Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Wuu J, Mathis CA, Scheff SW, Mufson EJ, DeKosky ST.

Neurology. 2011 Jul 5;77(1):39-47. doi: 10.1212/WNL.0b013e3182231419. Epub 2011 Jun 22.

2.

Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Perez SE, He B, Nadeem M, Wuu J, Scheff SW, Abrahamson EE, Ikonomovic MD, Mufson EJ.

Biol Psychiatry. 2015 Apr 15;77(8):693-703. doi: 10.1016/j.biopsych.2013.12.016. Epub 2014 Jan 11.

3.

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ.

Ann Neurol. 2002 Feb;51(2):145-55.

PMID:
11835370
4.

[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients.

Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, Långström B.

Neurochem Int. 2009 May-Jun;54(5-6):347-57. doi: 10.1016/j.neuint.2008.12.016. Epub 2008 Dec 30.

PMID:
19162107
5.

Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, Klunk WE.

J Neurosci. 2009 Nov 25;29(47):14770-8. doi: 10.1523/JNEUROSCI.3669-09.2009.

6.

Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.

Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A.

Brain. 2013 Jul;136(Pt 7):2217-27. doi: 10.1093/brain/awt142. Epub 2013 Jun 11.

PMID:
23757761
7.

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.

Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1304-14. doi: 10.1007/s00259-016-3359-8. Epub 2016 Mar 22.

PMID:
27003417
8.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Laforce R Jr, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014.

9.

Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.

Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, Kraut MA, Ferrucci L, Mathis CA, Klunk WE, O'Brien RJ, Davatzikos C, Wong DF, Resnick SM.

Acta Neuropathol. 2012 Dec;124(6):823-31. doi: 10.1007/s00401-012-1025-1. Epub 2012 Aug 5.

10.

Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity.

Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A.

Neurobiol Aging. 2012 Apr;33(4):825.e1-13. doi: 10.1016/j.neurobiolaging.2011.05.003. Epub 2011 Jun 17.

PMID:
21683475
11.

Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.

Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, Lammertsma A, Scheltens P, van Berckel B, van der Flier W.

J Alzheimers Dis. 2014;41(3):801-7. doi: 10.3233/JAD-132561.

PMID:
24705549
12.

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.

Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Någren K, Rinne JO, Soininen H.

Dement Geriatr Cogn Disord. 2008;26(4):378-83. doi: 10.1159/000163927. Epub 2008 Oct 16.

PMID:
18931497
13.

Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.

Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A.

J Nucl Med. 2012 Jan;53(1):37-46. doi: 10.2967/jnumed.110.087031.

14.

Imaging beta-amyloid burden in aging and dementia.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL.

Neurology. 2007 May 15;68(20):1718-25.

PMID:
17502554
15.

Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology.

Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST.

J Alzheimers Dis. 2003 Feb;5(1):39-48.

PMID:
12590165
16.

Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.

Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, Lah JJ, Ghiso JA, LeVine H 3rd, Walker LC.

Acta Neuropathol. 2010 Feb;119(2):221-33. doi: 10.1007/s00401-009-0583-3. Epub 2009 Aug 19.

17.

Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A.

Biol Psychiatry. 2009 Jun 1;65(11):927-34. doi: 10.1016/j.biopsych.2009.01.027. Epub 2009 Mar 6.

18.

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2007 May 8;68(19):1603-6.

PMID:
17485647
19.

Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.

Tzen KY, Yang SY, Chen TF, Cheng TW, Horng HE, Wen HP, Huang YY, Shiue CY, Chiu MJ.

ACS Chem Neurosci. 2014 Sep 17;5(9):830-6. doi: 10.1021/cn500101j. Epub 2014 Aug 13.

PMID:
25054847
20.

Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression.

Beckett TL, Webb RL, Niedowicz DM, Holler CJ, Matveev S, Baig I, LeVine H 3rd, Keller JN, Murphy MP.

J Alzheimers Dis. 2012;32(1):127-38.

Supplemental Content

Support Center